NCT04383743View on ClinicalTrials.gov

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

June 17, 2024

Study Completion Date

March 4, 2025

Conditions
Stage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8Muscle Invasive Bladder Carcinoma
Interventions
DRUG

Cisplatin

Given IV

DRUG

Doxorubicin

Given IV

DRUG

Methotrexate

Given IV

BIOLOGICAL

Pegfilgrastim

Given SC

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Radical Cystectomy

Undergo standard of care radical cystectomy

DRUG

Vinblastine Sulfate

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Washington

OTHER

NCT04383743 - Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter